NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON
Peptide testing

Ordered Retatrutide from BeiBangAn? Mail in a sample (US only) and let us test it.

Test my supply
+6 more ↓
78%
Finnrick rating
#184 of 419 Retatrutide vendors
29 of 38 classifiable tests passed
customers 4.6★ (36)
methodology · Purity focus
Finnrick analysis · Retatrutide

BeiBangAn Retatrutide's purity score is held down by early sub-99.5% results and one 80.7% purity test; recent classifiable tests mostly clear the threshold. Check fill swings, including +36% and -26%, which this method largely tolerates.

methodology →
vendor intelligence report
Vendor Intelligence Report: BeiBangAn

BBA’s public COA page now exists, but the certificate trail stops short of vial-level traceability. The report maps Hostinger staging fingerprints, LNpeptide build artifacts, lapsed domains, and Telegram copycat risk.

33 pages7 risk factors assessed12 Nov 2026
read the report
Peptides
#
Peptide
$/MG
Rating
N
1
GHK-Cu
$0.10
85%
5
2
Retatrutideselected
$0.70
78%
40
3
Tirzepatide
$0.34
76%
20
4
Semaglutide
$0.45
69%
4
5
PT-141
-
60%
3
6
BPC-157
$0.70
54%
4
8
Cagrilintide
$1.85
-
0
10
HGH
-
-
0
12
Melanotan II
$0.55
-
0
13
Sermorelin
$1.20
-
0
14
TB-500
$1.50
-
0
Contact channels
Rating trend
CUMULATIVE FINNRICK RATING
83%+65%+48%+30%+<30%29 Oct 2025: 71%17 Nov 2025: 67%17 Nov 2025: 63%23 Nov 2025: 64%2 Dec 2025: 66%2 Dec 2025: 67%2 Dec 2025: 63%2 Dec 2025: 60%5 Dec 2025: 61%11 Dec 2025: 63%16 Dec 2025: 64%18 Dec 2025: 66%29 Dec 2025: 68%1 Jan 2026: 65%7 Jan 2026: 62%7 Jan 2026: 63%15 Jan 2026: 65%20 Feb 2026: 67%20 Feb 2026: 64%26 Feb 2026: 65%26 Feb 2026: 66%1 Mar 2026: 67%1 Mar 2026: 68%13 Mar 2026: 70%13 Mar 2026: 71%18 Mar 2026: 72%28 Apr 2026: 73%8 May 2026: 74%27 May 2026: 71%26 Jun 2026: 72%10 Jul 2026: 73%12 Aug 2026: 74%18 Aug 2026: 75%21 Aug 2026: 75%13 Oct 2026: 76%5 Nov 2026: 77%5 Nov 2026: 77%6 Nov 2026: 78%15 Nov 2026: current 78%71%70%78%Oct 25Nov 26
Showing Retatrutide tests only
Peptide testing

Ordered Retatrutide from BeiBangAn? Mail in a sample (US only) and let us test it.

Test my supply
BeiBangAn Retatrutide test history
COA-backed lab tests
1-10 of 40

About BeiBangAn test results from Finnrick

BeiBangAn is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 7 peptides and 77 tests, including ratings, observed price signals, recent test dates, and correction history where available.

Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.

The most visible BeiBangAn peptides in this dataset are BPC-157 (4 tests), GHK-Cu (5 tests) and PT-141 (3 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.

Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 77 recent tests. It also includes 1 correction related to this vendor.

Corrections
2026-03-11
Lab correction
Requester asked for a review, the lab issued an updated COA: blank correction was not accounted for in the previous analysis, resulting in an incorrect purity reading of 97.4%.
Peptide testing

Ordered Retatrutide from BeiBangAn? Mail in a sample (US only) and let us test it.

Test my supply